There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines ...
Since HIV’s discovery in the 1980s, scientists have come a long way in understanding the different steps required for its assembly and maturation. Researchers knew, for instance, that HIV wraps its ...
A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...
Smuggling its genome into the nucleus is essential for HIV to infect its host, but entering the cell’s control center is no easy feat. Molecules must pass through tightly-regulated nuclear pores on ...
Thumbi Ndung’u consults for Gilead Sciences, Inc. He has received HIV cure-related research grants from Gilead Sciences, Inc, the US NIH, Bill and Melinda Gates Foundation, Wellcome Trust and SFA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback